Journal of Microbiology and Biotechnology

The Korean Society for Microbiology and Biotechnology (한국미생물·생명공학회)
권호 표지
DOI QR코드

DOI QR Code

Immune Effect of Newcastle Disease Virus DNA Vaccine with C3d as a Molecular Adjuvant

  • Zhao, Kai (Key Laboratory of Microbiology, School of Life Science, Heilongjiang University) ;
  • Duan, Xutong (Key Laboratory of Microbiology, School of Life Science, Heilongjiang University) ;
  • Hao, Lianwei (Key Laboratory of Microbiology, School of Life Science, Heilongjiang University) ;
  • Wang, Xiaohua (Key Laboratory of Microbiology, School of Life Science, Heilongjiang University) ;
  • Wang, Yunfeng (Division of Avian Infectious Diseases, State Key Laboratory of Veterinary Biotechnology, Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences)
  • Received : 2017.08.09
  • Accepted : 2017.10.15
  • Published : 2017.11.28
Download PDF
⟨ Previous Next ⟩

Abstract

Newcastle disease is a serious infectious disease in the poultry industry. The commercial vaccines can only offer limited protection and some of them are expensive and need adjuvants. At present, DNA vaccines are widely used. However, the immune responses induced by DNA vaccines are too slow and low. Here, we constructed the transfer vectors with a different number of C3d as molecular adjuvants (n = 1, 2, 4, or 6), and the vectors were cloned into the optimal eukaryotic expression plasmid (pVAXI-optiF) that expressed the F gene of Newcastle disease virus (NDV), and named pVAXI-F(o)-C3d1, pVAXI -F(o)-C3d2, pVAXI-F(o)-C3d4, and pVAXI-F(o)-C3d6, respectively. Cell transfection test indicated that pVAXI-F(o)-C3d6 showed the highest expression. In vivo immunization showed that the chickens immunized with pVAXI-F(o)-C3d6 intramuscularly induced better immune responses than the chickens immunized with the other plasmids. The protective efficacy of pVAXI-F(o)-C3d6 was 80% after challenge with the highly virulent NDV strain F48E9. The results in this study showed that C3d6 could be used as a molecular adjuvant to quickly induce an effective immune response to control NDV.

Keywords

References

  1. Steglich C, Grund C, Roder O, Zhao N, Mettenleitera TC, Romer-Oberdorfera A. 2014. Chimeric avian paramyxovirusbased vector immunization against highly pathogenic avian influenza followed by conventional Newcastle disease vaccination eliminates lack of protection from virulent ND virus. Trials Vaccinol. 3: 65-72. https://doi.org/10.1016/j.trivac.2014.03.002
  2. Miller PJ, Haddas R, Simanov L, Lublin A, Rehmani SF, Wajid A, et al. 2015. Identification of new sub-genotypes of virulent Newcastle disease virus with potential panzootic features. Infect. Genet. Evol. 29: 216-229. https://doi.org/10.1016/j.meegid.2014.10.032
  3. Hao HF, Chen SL, Liu P, Ren S, Gao X, Wang Y, et al. 2016. Genetic variation in V gene of class II Newcastle disease virus. Infect. Genet. Evol. 37: 14-20. https://doi.org/10.1016/j.meegid.2015.10.020
  4. DiNapoli JM, Ward JM, Cheng L, Yang L, Elankumaran S, Murphy BR, et al. 2009. Delivery to the lower respiratory tract is required for effective immunization with Newcastle disease virus-vectored vaccines intended for humans. Vaccine 27: 1530-1539. https://doi.org/10.1016/j.vaccine.2009.01.009
  5. Wu Y, He J, An Y, Wang X, Liu Y, Yan S, et al. 2016. Recombinant Newcastle disease virus (NDV/Anh-IL-2) expressing human IL-2 as a potential candidate for suppresses growth of hepatoma therapy. J. Pharmacol. Sci. 132: 24-30. https://doi.org/10.1016/j.jphs.2016.03.012
  6. Morla S, Shah M, Kaore M, Kurkure NV, Kumar S. 2016. Molecular characterization of genotype XIIIb Newcastle disease virus from central India during 2006-2012: evidence of its panzootic potential. Microb. Pathog. 99: 83-86. https://doi.org/10.1016/j.micpath.2016.08.005
  7. Dimitrov KM, Ramey AM, Qiu X, Bahl J, Afonso CL. 2016. Temporal, geographic, and host distribution of avian paramyxovirus 1 (Newcastle disease virus). Infect. Genet. Evol. 39: 22-34. https://doi.org/10.1016/j.meegid.2016.01.008
  8. Dortmans JC, Rottier PJ, Koch G, Peeters BP. 2010. The viral replication complex is associated with the virulence of Newcastle disease virus. J. Virol. 84: 10113-10120. https://doi.org/10.1128/JVI.00097-10
  9. Wang J, Lv Y, Zhang Y, Zheng D, Zhao Y, Castellan D, et al. 2016. Genomic characterizations of a Newcastle disease virus isolated from ducks in live bird markets in China. PLoS One 11: e0158771. https://doi.org/10.1371/journal.pone.0158771
  10. Liu XF, Wan HQ, Ni XX, Wu YT, Liu WB. 2003. Pathotypical and genotypical characterization of Newcastle disease virus isolated from outbreaks in chicken and goose flocks in some regions of China during 1985-2001. Arch. Virol. 148: 1387-1403.
  11. Nagai Y, Klenk HD, Rott R. 1976. Proteolytic cleavage of the viral glycoproteins and its significance for the virulence of Newcastle disease virus. Virology 72: 494-508. https://doi.org/10.1016/0042-6822(76)90178-1
  12. Cardenas-Garcia S, Diel DG, Susta L, Lucio-Decanini E, Yu Q, Brown CC, et al. 2015. Development of an improved vaccine evaluation protocol to compare the efficacy of Newcastle disease vaccines. Biologicals 43: 136-45. https://doi.org/10.1016/j.biologicals.2014.11.003
  13. Cardenas-Garcia S, Dunwoody RP, Marcano V, Diel DG, Williams RJ, Gogal RM Jr, et al. 2016. Effects of chicken interferon gamma on Newcastle disease virus vaccine immunogenicity. PLoS One 11: e0159153. https://doi.org/10.1371/journal.pone.0159153
  14. Wang G, Zhu R, Yang L, Wang K, Zhang Q, Su X, et al. 2016. Non-thermal plasma for inactivated-vaccine preparation. Vaccine 34: 1126-1132. https://doi.org/10.1016/j.vaccine.2015.10.099
  15. Kim SH, Samal SK. 2016. Newcastle disease virus as a vaccine vector for development of human and veterinary vaccines. Viruses 8: 2-15.
  16. Kumar S. 2015. Newcastle disease virus outbreaks in India:time to revisit the vaccine type and strategies. Vaccine 33:3268-3269. https://doi.org/10.1016/j.vaccine.2015.03.003
  17. Baxter D. 2007. Active and passive immunity, vaccine types, excipients and licensing. Occup. Med. 57: 552-556. https://doi.org/10.1093/occmed/kqm110
  18. Xu GL, Zhang KQ, Guo B, Zhao TT, Yang F, Jiang M, et al. 2010. Induction of protective and therapeutic antitumor immunity by a DNA vaccine with C3d as a molecular adjuvant. Vaccine 28: 7221-7227. https://doi.org/10.1016/j.vaccine.2010.08.057
  19. Ramezanpour B, de Foucauld J, Kortekaas J. 2016. Emergency deployment of genetically engineered veterinary vaccines in Europe. Vaccine 34: 3435-3440. https://doi.org/10.1016/j.vaccine.2016.05.013
  20. Tlaxca JL, Ellis S, Remmele RL Jr. 2015. Live attenuated and inactivated viral vaccine formulation and nasal delivery:potential and challenges. Adv. Drug Deliv. Rev. 93: 56-78. https://doi.org/10.1016/j.addr.2014.10.002
  21. Li L, Petrovsky N. 2016. Molecular mechanisms for enhanced DNA vaccine immunogenicity. Expert Rev. Vaccines 15: 313-329
  22. Oreskovic Z, Kudlackova H, Krejci J, Nechvatalova K, Faldyna M. 2017. Oil-based adjuvants delivered intradermally induce high primary IgG2 immune response in swine. Res. Vet. Sci. 114: 41-43. https://doi.org/10.1016/j.rvsc.2017.03.007
  23. Crepeaux G, Eidi H, David M, Baba-Amer Y. 2017. Nonlinear dose-response of aluminium hydroxide adjuvant particles: selective low dose neurotoxicity. Toxicology 375:48-57. https://doi.org/10.1016/j.tox.2016.11.018
  24. Buonavoglia D, Greco G, Corrente M, D'Abramo M. 2010. Long-term immunogenicity and protection against Mycoplasma agalactiae induced by an oil adjuvant vaccine in sheep. Res. Vet. Sci. 88: 16-19. https://doi.org/10.1016/j.rvsc.2009.07.006
  25. Dempsey PW, Allison ME, Akkaraju S, Goodnow CC, Fearon DT. 1996. C3d of complement as a molecular adjuvant:bridging innate and acquired immunity. Science 271: 348-350. https://doi.org/10.1126/science.271.5247.348
  26. Zhao K, Rong G, Guo C, Luo X, Kang H, Sun Y, et al. 2015. Synthesis, characterization and immune efficacy of LDH@$SiO_2$ nanoparticles with shell-core structure as a delivery carrier for Newcastle disease virus DNA vaccine. Int. J. Nanomedicine 10: 2895-2911.
  27. Wang R, Richie TL, Baraceros MF, Rahardjo N, Gay T, Banania JG, et al. 2005. Boosting of DNA vaccine-elicited gamma interferon responses in humans by exposure to malaria parasites. Infect. Immun. 73: 2863-2872. https://doi.org/10.1128/IAI.73.5.2863-2872.2005
  28. Zhang Y, Guo J, Li L, Liu X, Yao X, Liu H. 2016. The solvent at antigen-binding site regulated C3d-CR2 interactions through the C-terminal tail of C3d at different ion strengths:insights from molecular dynamics simulation. Biochem. Biophys. Acta 1860: 2220-2231. https://doi.org/10.1016/j.bbagen.2016.05.002
  29. Li GX, Zhou YJ, Yu H, Tian ZJ, Yan LP, Zhang Q, et al. 2010. Prime-boost immunization with HA/C3d DNA followed by a recombinant pseudorabies virus boost enhanced protective immunity against H3N2 swine influenza virus in mice. Res. Vet. Sci. 88: 345-351. https://doi.org/10.1016/j.rvsc.2009.09.005
  30. Musa HH, Zhang WJ, Tao J, Guan YK, Duan XL, Yang Y, et al. 2014. Cloning and expression of FimA-C3d recombinant protein. J. Genet. Eng. Biotechnol. 12: 55-59. https://doi.org/10.1016/j.jgeb.2014.03.005
  31. Suradhat S, Braun RP, Lewis PJ, Babiuk LA, van Drunen Littel-van den Hurk S, Griebel PJ, et al. 2001. Fusion of C3d molecule with bovine rotavirus VP7 or bovine herpesvirus type 1 glycoprotein D inhibits immune responses following DNA immunization. Vet. Immunol. Immunopathol. 83: 79-92. https://doi.org/10.1016/S0165-2427(01)00369-5
  32. Liu D, Niu ZX. 2008. Cloning of a gene fragment encoding chicken complement component C3d with expression and immunogenicity of Newcastle disease virus F gene-C3d fusion protein. Avian Pathol. 37: 477-485. https://doi.org/10.1080/03079450802356920

Cited by

  1. Diagnostic and Vaccination Approaches for Newcastle Disease Virus in Poultry: The Current and Emerging Perspectives vol.2018, pp.None, 2018, https://doi.org/10.1155/2018/7278459
  2. A candidate DNA vaccine encoding a fusion protein of porcine complement C3d-P28 and ORF2 of porcine circovirus type 2 induces cross-protective immunity against PCV2b and PCV2d in pigs vol.16, pp.None, 2017, https://doi.org/10.1186/s12985-019-1156-2
  3. Zika Virus Proteins NS2A and NS4A Are Major Antagonists that Reduce IFN-β Promoter Activity Induced by the MDA5/RIG-I Signaling Pathway vol.29, pp.10, 2019, https://doi.org/10.4014/jmb.1909.09017
  4. Immune effect of a Newcastle disease virus DNA vaccine with IL-12 as a molecular adjuvant delivered by electroporation vol.165, pp.9, 2017, https://doi.org/10.1007/s00705-020-04669-5
  5. Intranasal immunization with O-2′-Hydroxypropyl trimethyl ammonium chloride chitosan nanoparticles loaded with Newcastle disease virus DNA vaccine enhances mucosal immune response in chickens vol.19, pp.1, 2017, https://doi.org/10.1186/s12951-021-00983-5